401 results
8-K
IMGN
Immunogen, Inc.
12 Feb 24
Termination of a Material Definitive Agreement
7:52am
tax withholdings, equal to (i) the total number of Company Common Shares subject to such Company Stock Option immediately prior to the Effective Time … and in exchange therefor the holder became entitled to receive in cash, without interest and less applicable tax withholdings, an amount equal
DEFM14A
IMGN
Immunogen, Inc.
2 Jan 24
Proxy related to merger
4:26pm
of ImmunoGen’s Directors and Executive Officers in the Merger
Appraisal Rights
Certain Material U.S. Federal Income Tax Consequences of the Merger
PREM14A
IMGN
Immunogen, Inc.
21 Dec 23
Preliminary proxy related to merger
4:52pm
Opinion of Lazard
Interests of ImmunoGen’s Directors and Executive Officers in the Merger
Appraisal Rights
Certain Material U.S. Federal Income Tax … Information
Interests of ImmunoGen’s Directors and Executive Officers in the Merger
Appraisal Rights
Certain Material U.S. Federal Income Tax
DEFA14A
IMGN
Immunogen, Inc.
30 Nov 23
Additional proxy soliciting materials
4:07pm
will be cancelled and in exchange therefor the holder will be entitled to receive an amount in cash, without interest and less applicable tax withholdings, equal … the holder will be entitled to receive in cash, without interest and less applicable tax withholdings, an amount equal to the product of (x) the total
DEFA14A
EX-2.1
IMGN
Immunogen, Inc.
30 Nov 23
Additional proxy soliciting materials
4:07pm
Properties
Section 3.12.
Tax Matters
Section 3.13.
Contracts and Commitments
Section 3.14.
Intellectual Property
Section 3.15.
Litigation
Section 3.16 … of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings pursuant to Section 2.6) equal to the product of (x
8-K
87f60sgsa0 nb6m
30 Nov 23
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
4:05pm
8-K
EX-2.1
9csb znewuze
30 Nov 23
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
4:05pm
8-K
EX-99.1
23zo57
2 Nov 23
ImmunoGen Reports Recent Progress and Third Quarter 2023 Financial Results
6:35am
8-K
EX-99.1
lg8 lhq6eketuozs9tw
31 Jul 23
ImmunoGen Reports Recent Progress and Second Quarter 2023 Financial Results
6:40am
8-K
EX-1.1
bh3lzze455c
5 May 23
Entry into a Material Definitive Agreement
5:15pm
424B5
epa3ws f0l
5 May 23
Prospectus supplement for primary offering
4:49pm
424B5
le649mw5cic39rt54crj
3 May 23
Prospectus supplement for primary offering
4:05pm
8-K
EX-3.1
xoisnbnszclon
2 May 23
Entry into a Material Definitive Agreement
5:01pm
8-K
EX-10.1
8hohtn8aiaoxcwhni
2 May 23
Entry into a Material Definitive Agreement
5:01pm